Objective Capital Partners is pleased to announce the addition of Matthew Pelo to the OCP team. In his role as Vice President, Matt brings valuable strategic insights and finance expertise to OCP’s clients. His leadership experience and extensive work in the areas of Genomics and Technology make him an outstanding addition to OCP’s senior team and further strengthen OCP’s Life Sciences and Healthcare Practice Group. With a proven ability to achieve exceptional results, Matt further enhances OCP’s ability to deliver premium investment banking and advisory services to our valued clients.
Cautiously optimistic. That is the tone for the Healthcare and Life Sciences Sector as we head into 2019. Many of us who attended JPMorgan’s Healthcare conference earlier this year in San Francisco, CA, walked away feeling this tone. Despite the ongoing stock market volatility, continuing Affordable Care Act (ACA) challenges, ongoing evolution of regulations, reimbursement policies and delivery models, and risk of a rise in drug price rhetoric in the United States, many are maintaining an optimistic stance for increased growth and efficiency opportunities.
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.